• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[抗维生素K引起的颅内出血并发症的原因]

[The causes of intracranial hemorrhagic complications induced by antivitamins K].

作者信息

Lacroix P, Portefaix O, Boucher M, Ramiandrisoa H, Dumas M, Ravon R, Christides C, Laskar M

机构信息

Service de CTCV et angiologie, CHRU Dupuytren, Limoges.

出版信息

Arch Mal Coeur Vaiss. 1994 Dec;87(12):1715-9.

PMID:7786112
Abstract

Cerebral haemorrhage is the main life-threatening complication of oral anticoagulant therapy. In order to identify a means of prevention, the authors undertook a retrospective study of 68 consecutive cases of anticoagulant-related intracerebral haemorrhage. The mortality was 38.5%. The respective frequency of intracerebral haemorrhage, subarachnoid haemorrhage, acute and chronic subdural haematomas was 63.2, 16.2, 10.3 and 10.3%, respectively. On admission, nearly half the patients (53%) had prothrombin ratios inferior to 25%. A predisposing factor was found in 58% of cases: hypertension (30.6%), head injury (14.5%), alcoholism or drug interaction (11.2%), and one case of intracerebral aneurysm. A history of a transient ischaemic attack or of a cerebrovascular accident was found in 10.2% of cases and 11.7% had a previous anticoagulant related extracranial haemorrhage. The initial indications for oral anticoagulation were ischaemic heart disease (32%), atrial fibrillation (20.5%), secondary prevention of venous thromboembolic disease (17.6%) and primary prevention of venous thrombosis (11.7%). The duration of treatment for isolated ischaemic heart disease was over 6 months in all cases: the average duration of treatment was 12.4 months in phlebitis and pulmonary embolism. A critical review of the indications of treatment in the light of recent recommendations showed that if inappropriate indications were rare, the sometimes unnecessary prolongation of treatment was more common. Nearly half of these cases were receiving anticoagulants when the potential benefits were questionable at the time of the haemorrhagic complication. Clinical and biological follow-up is necessary for patients on anticoagulants; minor bleeding complications may be the prelude to major haemorrhage. Biological follow-up is based on control of the international normalised ratio.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

脑出血是口服抗凝治疗主要的危及生命的并发症。为了确定预防方法,作者对68例连续的抗凝相关脑出血病例进行了回顾性研究。死亡率为38.5%。脑出血、蛛网膜下腔出血、急性和慢性硬膜下血肿的各自发生率分别为63.2%、16.2%、10.3%和10.3%。入院时,近一半患者(53%)的凝血酶原比率低于25%。58%的病例发现有诱发因素:高血压(30.6%)、头部损伤(14.5%)、酗酒或药物相互作用(11.2%)以及1例脑内动脉瘤。10.2%的病例有短暂性脑缺血发作或脑血管意外病史,11.7%曾有抗凝相关的颅外出血。口服抗凝治疗的初始指征为缺血性心脏病(32%)、房颤(20.5%)、静脉血栓栓塞性疾病的二级预防(17.6%)和静脉血栓形成的一级预防(11.7%)。所有单纯缺血性心脏病病例的治疗持续时间均超过6个月:静脉炎和肺栓塞的平均治疗持续时间为12.4个月。根据近期建议对治疗指征进行严格审查发现,虽然不恰当的指征很少见,但有时不必要的治疗延长更为常见。在出血并发症发生时,这些病例中近一半在接受抗凝治疗,而此时潜在益处存疑。对抗凝患者进行临床和生物学随访很有必要;轻微出血并发症可能是大出血的前奏。生物学随访基于国际标准化比值的监测。(摘要截选至250词)

相似文献

1
[The causes of intracranial hemorrhagic complications induced by antivitamins K].[抗维生素K引起的颅内出血并发症的原因]
Arch Mal Coeur Vaiss. 1994 Dec;87(12):1715-9.
2
[Prevention of thromboembolic complications with adapted low-dose of antivitamins K after total hip prosthesis].
Rev Chir Orthop Reparatrice Appar Mot. 1993;79(7):577-85.
3
[Indications and limitations of anticoagulant treatment in elderly patients].
Rev Prat. 1990 May 21;40(15):1375-8.
4
[Acute hemorrhage due anti-vitamin K agents. A prognostic and descriptive study].
Tunis Med. 2009 Nov;87(11):763-9.
5
[Antithrombotic therapy of atrial fibrillation].[心房颤动的抗栓治疗]
Arch Mal Coeur Vaiss. 1996 Nov;89(11 Suppl):1533-42.
6
[Congenital cardiopathy: indications for anticoagulant treatment].
Arch Mal Coeur Vaiss. 2005 May;98(5):566-70.
7
[Intracranial hemorrhages associated with oral anticoagulant therapy. Analysis of 38 cases].
Therapie. 2002 May-Jun;57(3):297-301.
8
[Duration of antivitamin K therapy in venous thromboembolic disease. Certainties and uncertainties].
Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1301-6.
9
Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.维生素K拮抗剂过度抗凝的危险因素。一项针对未筛选的急诊科患者的病例对照研究。
Thromb Haemost. 2008 Oct;100(4):685-92.
10
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.非风湿性心房颤动合并出血风险患者的口服抗凝治疗。一项多中心起始队列研究。
Thromb Haemost. 2001 Mar;85(3):418-22.

引用本文的文献

1
Risk Factors for Anticoagulant-Associated Intracranial Hemorrhage: A Systematic Review and Meta-analysis.抗凝相关颅内出血的危险因素:系统评价和荟萃分析。
Neurocrit Care. 2023 Jun;38(3):812-820. doi: 10.1007/s12028-022-01671-4. Epub 2023 Jan 20.
2
[Accidents in patients under anticoagulant therapy in the Department of Cardiology at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou (Burkina Faso)].[瓦加杜古(布基纳法索)亚尔加杜·韦德拉奥果教学医院心脏病科接受抗凝治疗患者的事故情况]
Pan Afr Med J. 2018 Feb 27;29:135. doi: 10.11604/pamj.2018.29.135.10650. eCollection 2018.